China Jo-Jo Drugstores, Inc. (CJJD)
USD 1.52
(-5.59%)
USD 1.52
(-5.59%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 80.76 Million USD | 8.69% |
| 2023 | 74.3 Million USD | -11.17% |
| 2022 | 83.64 Million USD | 2.12% |
| 2021 | 81.9 Million USD | 1.45% |
| 2020 | 80.73 Million USD | 44.8% |
| 2019 | 55.75 Million USD | 1.47% |
| 2018 | 54.95 Million USD | 35.65% |
| 2017 | 40.5 Million USD | -5.26% |
| 2016 | 42.75 Million USD | 1.14% |
| 2015 | 42.27 Million USD | 34.02% |
| 2014 | 31.54 Million USD | 6.25% |
| 2013 | 29.69 Million USD | 31.32% |
| 2012 | 22.6 Million USD | 90.47% |
| 2011 | 11.87 Million USD | 59.69% |
| 2010 | 7.43 Million USD | 84372.59% |
| 2009 | 8800.00 USD | 0.0% |
| 2008 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 80.76 Million USD | 0.0% |
| 2024 Q1 | 77.22 Million USD | 3.94% |
| 2024 Q3 | 80.76 Million USD | 4.58% |
| 2024 FY | 80.76 Million USD | 8.69% |
| 2024 Q2 | 77.22 Million USD | 0.0% |
| 2023 Q3 | 74.3 Million USD | -6.93% |
| 2023 FY | 74.3 Million USD | -11.17% |
| 2023 Q1 | 79.83 Million USD | -4.56% |
| 2023 Q2 | 79.83 Million USD | 0.0% |
| 2023 Q4 | 74.3 Million USD | 0.0% |
| 2022 Q1 | 92.52 Million USD | 12.96% |
| 2022 FY | 83.64 Million USD | 2.12% |
| 2022 Q4 | 83.64 Million USD | 0.0% |
| 2022 Q3 | 83.64 Million USD | -9.59% |
| 2022 Q2 | 92.52 Million USD | 0.0% |
| 2021 Q1 | 72.72 Million USD | -9.92% |
| 2021 Q3 | 76.47 Million USD | -2.12% |
| 2021 FY | 81.9 Million USD | 1.45% |
| 2021 Q2 | 78.13 Million USD | 7.43% |
| 2021 Q4 | 81.9 Million USD | 7.11% |
| 2020 Q2 | 65.52 Million USD | 15.52% |
| 2020 FY | 80.73 Million USD | 44.8% |
| 2020 Q3 | 63.37 Million USD | -3.29% |
| 2020 Q4 | 80.73 Million USD | 27.41% |
| 2020 Q1 | 56.72 Million USD | 1.72% |
| 2019 Q3 | 53.32 Million USD | 7.86% |
| 2019 Q1 | 46.35 Million USD | -15.64% |
| 2019 FY | 55.75 Million USD | 1.47% |
| 2019 Q4 | 55.75 Million USD | 4.57% |
| 2019 Q2 | 49.43 Million USD | 6.64% |
| 2018 Q2 | 44.3 Million USD | 12.67% |
| 2018 FY | 54.95 Million USD | 35.65% |
| 2018 Q4 | 54.95 Million USD | 12.17% |
| 2018 Q3 | 48.98 Million USD | 10.56% |
| 2018 Q1 | 39.32 Million USD | -2.92% |
| 2017 Q2 | 40.95 Million USD | 15.24% |
| 2017 Q1 | 35.53 Million USD | -16.88% |
| 2017 FY | 40.5 Million USD | -5.26% |
| 2017 Q4 | 40.5 Million USD | 19.84% |
| 2017 Q3 | 33.8 Million USD | -17.47% |
| 2016 Q1 | 45.02 Million USD | 6.5% |
| 2016 FY | 42.75 Million USD | 1.14% |
| 2016 Q4 | 42.75 Million USD | 4.51% |
| 2016 Q3 | 40.91 Million USD | -7.21% |
| 2016 Q2 | 44.08 Million USD | -2.08% |
| 2015 Q3 | 38.54 Million USD | 12.17% |
| 2015 Q4 | 42.27 Million USD | 9.69% |
| 2015 FY | 42.27 Million USD | 34.02% |
| 2015 Q1 | 28.86 Million USD | -8.49% |
| 2015 Q2 | 34.36 Million USD | 19.03% |
| 2014 Q3 | 37.68 Million USD | 16.4% |
| 2014 FY | 31.54 Million USD | 6.25% |
| 2014 Q1 | 31.48 Million USD | 6.06% |
| 2014 Q4 | 31.54 Million USD | -16.29% |
| 2014 Q2 | 32.37 Million USD | 2.81% |
| 2013 Q4 | 29.69 Million USD | -10.08% |
| 2013 FY | 29.69 Million USD | 31.32% |
| 2013 Q1 | 30.75 Million USD | 36.02% |
| 2013 Q2 | 36.68 Million USD | 19.28% |
| 2013 Q3 | 33.01 Million USD | -9.99% |
| 2012 Q3 | 16.37 Million USD | -0.26% |
| 2012 Q1 | 10.13 Million USD | -14.64% |
| 2012 Q4 | 22.6 Million USD | 38.09% |
| 2012 FY | 22.6 Million USD | 90.47% |
| 2012 Q2 | 16.41 Million USD | 62.01% |
| 2011 FY | 11.87 Million USD | 59.69% |
| 2011 Q1 | 9.37 Million USD | 26.18% |
| 2011 Q4 | 11.87 Million USD | 21.15% |
| 2011 Q3 | 9.79 Million USD | 35.84% |
| 2011 Q2 | 7.21 Million USD | -23.1% |
| 2010 Q2 | 9.51 Million USD | 108073.75% |
| 2010 Q1 | 8800.00 USD | -7.06% |
| 2010 FY | 7.43 Million USD | 84372.59% |
| 2010 Q4 | 7.43 Million USD | -10.13% |
| 2010 Q3 | 8.27 Million USD | -13.11% |
| 2009 Q4 | 9468.00 USD | 82.08% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | 8800.00 USD | 0.0% |
| 2009 Q3 | 5200.00 USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | 5.38 Million USD | -1399.18% |
| BIMI International Medical Inc. | 30.49 Million USD | -164.824% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 241.75 Million USD | 66.592% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 241.75 Million USD | 66.592% |
| Leafly Holdings, Inc. | 34.29 Million USD | -135.511% |
| Leafly Holdings, Inc. | 34.29 Million USD | -135.511% |
| LifeMD, Inc. | 52.91 Million USD | -52.631% |
| LifeMD, Inc. | 52.91 Million USD | -52.631% |
| TRxADE HEALTH, Inc. | 11.99 Million USD | -573.563% |
| PetMed Express, Inc. | 78.36 Million USD | -3.065% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.883% |